SEC Comment Letter 0000000000-24-003913 to Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc.
Date: April 11, 2024 · CIK: 0001907108 · Accession: 0000000000-24-003913
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278566
Letter
United States securities and exchange commission logo April 11, 2024 Jenny Robertson Chief Legal and Business Officer Lexeo Therapeutics, Inc. 345 Park Avenue South , Floor 6 New York , New York , 10010 Re:Lexeo Therapeutics, Inc. Registration Statement on Form S-1 Filed April 9, 2024 File No. 333-278566 Dear Jenny Robertson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Megan Baier
Show Raw Text
United States securities and exchange commission logo
April 11, 2024
Jenny Robertson
Chief Legal and Business Officer
Lexeo Therapeutics, Inc.
345 Park Avenue South , Floor 6
New York , New York , 10010
Re:Lexeo Therapeutics, Inc.
Registration Statement on Form S-1
Filed April 9, 2024
File No. 333-278566
Dear Jenny Robertson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Megan Baier